Isocitrate dehydrogenase (IDH) mutations and co-deletion of chromosome arms 1p and 19q (1p/19q) favor longer survival of GBM patients and are important molecular biomarkers for the diagnosis and treatment of GBM [48, 49]. Here, IDH3A is linked to glioblastoma.